Perspective Chapter: Epilepsy and Pregnancy

*Pavel Vlasov* 

#### **Abstract**

Currently, there are approximately 15 million women of childbearing age worldwide. A total of 0.3–0.4% of newborns are born to mothers with epilepsy, with nearly half a percent of these women experiencing ongoing seizures. This chapter addresses issues related to pregnancy preparation, the prognostic influence of seizure frequency, epilepsy type, and course on pregnancy outcomes, as well as potential risks associated with the condition for both the mother and the fetus. Summary data on latest recommendations for therapy adjustments and data on the pharmacokinetic changes of antiepileptic drugs during pregnancy are provided. The classification of antiepileptic drugs based on their teratogenic potential and their impact on child development and behavior is presented. Various approaches to managing pregnancy are discussed. Scenarios for managing pregnancy in cases of poorly controlled epilepsy and status epilepticus, as well as therapy adjustments in the postpartum period and measures for the safe care of newborns, are also considered.

**Keywords:** epilepsy, pregnancy, pregnant women with epilepsy, preparation for pregnancy, management of pregnancy, antiseizure drugs, postpartum, teratogenesis, major congenital malformations

#### **1. Introduction**

The management of pregnancy in women with epilepsy (WWE) is a relevant issue, considering the estimated global population of around 15 million women of reproductive age [1]. Statistical reports indicate that approximately 0.3–0.4% of newborns are born to mothers with epilepsy. Furthermore, the improved effectiveness of epilepsy therapy in the past two decades, with the use of new antiseizure drugs (ASDs), has led to a fourfold increase in pregnancies in women with epilepsy (WWE) [2]. The prevalence of active epilepsy among pregnant women is reported to be 0.33% [3], but other studies indicate a slightly higher rate of 0.49% [4]. Epileptic seizures rarely occur exclusively during pregnancy, which is known as gestational epilepsy.

#### **2. Epilepsy and pregnancy**

#### **2.1 Seizure control during pregnancy**

Several studies have indicated that the frequency of seizures during pregnancy remains unchanged [5]. However, when seizures have been in remission for 9 months or longer before conception, there is hope for their absence during pregnancy [6].

In a prospective observational multicenter cohort study conducted by Pennell et al. [5], the frequency of seizures during pregnancy and the first 6 weeks after delivery (*n* = 299) (observation period I) was compared with the frequency in the postpartum period (the subsequent 7.5 months after pregnancy) (period II). A control group (*n* = 93) consisted of nonpregnant women of similar age who were observed over an 18-month period. Patient demographics did not significantly differ between the groups. The primary outcome assessed was the percentage of women who experienced a higher frequency of seizures with impaired consciousness during period I compared to period II. Changes in ASD dosage were also evaluated in both groups. The results indicated that the frequency of seizures with impaired consciousness remained unchanged, worsened, or improved to a similar extent in both pregnant and nonpregnant women: unchanged frequency was reported in 63% of pregnant women and 65% of nonpregnant women, improvement in 14% and 11%, respectively, and worsening in 23% and 25%. In the pregnant group, 74% of the cases required a change in drug dosage or additional ASD prescription, while in the control group, dosage adjustments were necessary in only 31% of the cases [5].

According to the largest EURAP study (*n* = 3806 pregnancies), absence of seizures during pregnancy was observed in 66.6% of the cases. The rate increased to 73.6% for idiopathic generalized epilepsy (IGE) and decreased to 59.5% for focal epilepsy (FE) [7]. The average increase in ASD dosage from the first to the third trimester was 26% for lamotrigine, 5% for carbamazepine, 11% for phenobarbital, and 6% for valproate. The study reported 21 cases of epileptic status, 10 of which were convulsive, with no maternal mortality and only one case of stillbirth. The authors emphasize the need for more active adjustment of ASD dosages during pregnancy, particularly in cases of seizures occurring in the first trimester [7].

In a single-center study (114 pregnancies), Voinescu et al. [8] observed a significantly milder course of IGE and nonfrontal focal epilepsy during pregnancy, particularly when achieving seizure control for a 9-month period prior to pregnancy. A more detailed analysis of the results revealed that patients with frontal epilepsy experienced an increase in seizures during pregnancy (75%) when seizure control was not achieved before pregnancy, compared to an increase of 33% when seizure control was established prior to pregnancy. A similar disparity was observed in cases of focal epilepsy with different localizations; however, the percentage of seizure exacerbation was significantly lower (26% and 5%, respectively) [8].

In an observational cohort study conducted in Nigeria, a higher likelihood of seizures during pregnancy was observed in cases of structural focal epilepsy with posttraumatic (*P* = .013) and infectious etiology (*P* = .041). The authors also noted that the absence of seizures for less than 6 months before pregnancy had an unfavorable impact on pregnancy outcomes (*P* = .043) [3].

The review by Eadie [9] focuses on the analysis of seizure dynamics during pregnancy over the past 50 years. In the majority of studies, there was a predominant, albeit insignificant, trend toward worsened control of epileptic seizures during pregnancy. A detailed analysis of this worsening seizure control during pregnancy

*Perspective Chapter: Epilepsy and Pregnancy DOI: http://dx.doi.org/10.5772/intechopen.111957*


#### **Table 1.**

*Seizure dynamics during pregnancy according to Eadie (2021) [9] with supplemental data.*

identified several contributing factors, including the use of ASDs with lower teratogenic potential but less stable pharmacokinetics during pregnancy, noncompliance, the influence of steroid sex hormones on the estrogen/progesterone ratio, a more unfavorable course of focal epilepsy compared to generalized epilepsy, remission of seizures for less than 9–12 months before conception, and the use of monotherapy or polytherapy (polytherapy likely indicating pharmacoresistant disease) [9]. Additionally, negative influences on the course of epilepsy during pregnancy include nonadherence to a sleep-wake schedule (particularly in cases of generalized epilepsy), vomiting during pregnancy, anxiety, and depression [2].

As indicated in the **Table 1**, nearly all publications in the last 10 years report a predominance (sometimes minor) of increased seizure frequency during pregnancy compared to seizure reduction [9].

A limited number of studies have examined the dynamics of epilepsy during pregnancy in the absence of ASD therapy. The main conclusion drawn from observations of patients who refused to take ASDs during the first trimester or throughout their pregnancy is that their seizure frequency increased [14].

There are differing opinions regarding the influence of a previous pregnancy on the course of a current one. According to one viewpoint, an unfavorable course of a previous pregnancy increases the likelihood of decompensation in subsequent pregnancies. However, our experience suggests that such prediction is not possible [2].

**To summarize the key points on Seizure control during pregnancy:**


#### **2.2 Epileptic seizures: risk for mother and fetus**

The main objective of using ASDs is to prevent seizure occurrence during pregnancy, as they have unfavorable effects on both the mother and the fetus/child. Generalized tonic-clonic seizures and focal seizures to bilateral tonic-clonic seizures have the most harmful impact on the mother, including the possibility of traumatic brain injury, limb injury, spinal cord injuries, blunt abdominal trauma, hypoxia, lactic acidosis, etc. [2]. Sudden unexpected death in epilepsy (SUDEP) is also a concern [16]. These seizures can also have adverse effects on the fetus, such as asphyxia, hypoxia, and trauma [15]. All other seizures have minimal impact unless they are associated with falls of pregnant WWE [2]. Focal seizures with impaired consciousness have been described to cause a short-term fetal distress syndrome characterized by a decrease in fetal heart rate to 3.5 min [17].

The presence of seizures during pregnancy, regardless of classification, was reported to lead to decreased size and weight of the newborn as well as premature birth [18].

Currently, there is no evidence of a direct link between seizures and the occurrence of major congenital malformations (MCM) in the fetus [15]. However, certain conditions can increase the likelihood of MCM, such as prolonged generalized tonic-clonic seizures or status epilepticus, which can result in severe hypoxia and acidosis. Depending on the gestational age at which the seizure occurred, pregnancy outcomes vary. If there is a significant loss of germinal material miscarriage occurs. In case of complete regeneration of germinal material, structural defects do not develop. During the period of histogenesis and organogenesis, the development of MCM is possible, while in the second and third trimesters, the development of minor anomalies, developmental delays, and adverse cognitive and behavioral consequences may occur. Nevertheless, prospective studies have not yet confirmed the influence of generalized tonic-clonic seizures on the development of the nervous system [19, 20].

#### *2.2.1 Pharmacokinetics of ASD during pregnancy*

Significant changes in the pharmacokinetics of ASDs occur during pregnancy, starting from the early stages, including alterations in absorption, increased distribution volume, enhanced renal excretion, and induction of hepatic metabolism. **Table 2** presents summarized data on predicting ASD concentrations during pregnancy with an unchanged daily dose.

*Perspective Chapter: Epilepsy and Pregnancy DOI: http://dx.doi.org/10.5772/intechopen.111957*


#### **Table 2.**

*Summary data on prediction of individual ASD concentrations during pregnancy with unchanged daily dose of ASD (AED—antiepileptic drug) daily dose according to Tomson et al. [15] with modifications.*

As indicated in **Table 2**, the most unstable pharmacokinetics during pregnancy are observed when using phenobarbital (PHB), phenytoin (PHT), oxcarbazepine (OXC), lamotrigine (LTG), levetiracetam (LEV), ZNS, gababentin (GBP). Therefore, during pregnancy, the concentration of these ASDs should be monitored. In several studies by Harden et al. [6], Reisinger et al. [10], and Voinescu et al. [21], a critical decrease in ASD concentration was identified, which constituted 65% of the concentration before pregnancy [6, 10, 21]. Accordingly, a decrease in the concentration by just 35% can lead to an increase in epileptic seizures. If monitoring concentration is not possible, it is necessary to increase the daily dose of ASDs with variable pharmacokinetics by 30–50% in advance, especially in cases of unstable disease progression, short-term medication remission, initial difficulty in selecting therapy, structural focal epilepsy, history of generalized tonic-clonic seizures or focal seizures with impaired awareness, and with a minimal daily dose of ASDs [22].

#### *2.2.2 The impact of ASDs on fetal growth and development*

The impact of ASDs on fetal growth and development has been extensively studied using data from national registries and population-based studies, including those conducted in Australia, Denmark, Finland, Norway, Russia [23], EURAP, NAAPR, NEAD, Sweden, and the UK and Ireland Epilepsy and Pregnancy Registers. The findings suggest that the use of polytherapy during pregnancy, as well as monotherapy with Primidone, Phenobarbital, carbamazepine (CBZ), valproic acid (VPA), and newer ASDs such as topiramate (TPM) and zonisamide (ZNS), may be associated with varying degrees of intrauterine growth restriction, with TPM having the greatest negative impact [15]. The prospective NEAD study revealed an increased incidence of microcephaly with the use of VPA and CBZ during pregnancy, although by the age of 2 years, the child's head size was not significantly different from population norms (the measures were equalized) [24].

#### *2.2.3 Teratogenesis*

ASDs have been classified into categories based on their teratogenic potential, with LTG and LEV having minimal potential, pregabalin and TPM having moderate potential, and VPA having the highest potential (**Table 3**) [15]. However, the results of a nationwide cohort study conducted in France over a period of more than 4 years, involving all pregnancies ≥20 weeks (*n* = 1,886,825), did not show significant associations with major congenital malformations (MCM) for LTG, LEV, OXC, and CBZ [29]. For drugs with high and moderate risks of congenital malformations, there is a direct correlation between the increase in daily dosage and the frequency of MCM, particularly for VPA [15]. Furthermore, a specific organ-specificity of congenital malformation development has been demonstrated: for VPA, eight associations were identified, including spina bifida, four cardiovascular variants, facial anomalies, anorectal anomalies, and hypospadias. In the case of TPM, cleft palate and cleft lip were observed, while cardiac malformations were associated with the use of barbiturates (**Table 4**).

In recent years, the perspective on the use of bi- or polytherapy has shifted, focusing on the specific drugs involved rather than the fact of polytherapy itself. Data from the Australian registry indicate that any combination of ASDs with VPA and TPM is not recommended, whereas combining ASDs with LTG and LEV does not significantly increase the risk [28]. However, if the use of VPA and TPM during pregnancy cannot be avoided, it is advised to administer them at the minimum effective doses necessary to control generalized tonic-clonic seizures and focal to bilateral tonic-clonic seizures.

#### *2.2.4 Fetal anticonvulsant syndrome*

Fetal anticonvulsant syndrome, also known as fetal embryopathy or fetal anticonvulsant (primidone, hydantoin, phenobarbital, valproate, carbamazepine)


#### **Table 3.**

*Prevalence of major congenital malformations with monotherapy based on data from 4 prospective registries according to Tomson et al. [15] with supplemental information.*

*Perspective Chapter: Epilepsy and Pregnancy DOI: http://dx.doi.org/10.5772/intechopen.111957*


#### **Table 4.**

*ASDs and the associated MCMs according to Blotière et al. [29].*

syndrome, is a condition that occurs with the use of ASDs during pregnancy. It is characterized by minor structural abnormalities in the fetus that do not typically require treatment. Although this aspect of ASD use has received limited attention in recent scientific literature, information on this issue can be obtained from the Genetic and Rare Disease (GARD) website (https://rarediseases.info.nih.gov/diseases/6435/ fetal-hydantoin-syndrome).

#### *2.2.5 The impact of ASDs on child development and behavior*

In addition to structural teratogenesis, there is also a phenomenon known as "cognitive teratogenesis."

VPA takes precedence in terms of cognitive, as well as structural teratogenesis. The use of valproate during pregnancy in WWE is associated with a significant dose-dependent risk of cognitive impairments and developmental disorders of the nervous system in the child, as well as an increased occurrence of autistic spectrum disorders. In utero exposure to VPA has been correlated with developmental problems in infancy [30], decreased IQ and cognitive function impairments during childhood [31], and adolescence [32]. Prenatal exposure to VPA is also linked to a higher risk of developing autistic spectrum disorders, attention deficit hyperactivity disorder, and other behavioral problems [33]. There is a clear dose-dependent relationship, with even low doses of VPA (less than 400 mg/day) associated with decreased verbal IQ and increased need for educational assistance [19, 20, 34].

Research on the intrauterine effects of CBZ suggests that this drug does not cause serious neurobehavioral disorders. However, there are risks associated with reduced verbal reasoning skills [20, 35], as well as slightly poorer performance in mathematics compared to the control group, although the difference was not significant [36]. Previous data on the development of autism spectrum disorders were not confirmed in subsequent national cohort studies, large observational studies, or studies based on parents' assessments of autistic behavior symptoms in children [33].

Limited information is available regarding the effects of phenytoin monotherapy on cognitive and behavioral functions and socialization due to small sample sizes.

However, some studies have shown that children exposed to phenytoin have higher IQs compared to children exposed to VPA, and their IQs are comparable to those on CBZ and LTG monotherapy [19, 34].

The best outcomes have been observed in children born to mothers who received LTG during pregnancy, with their IQs being comparable to those of children in the control group [20]. Children exposed to intrauterine LTG exposure have shown better results in early development and school periods compared to children whose mothers received VPA [19]. Furthermore, no higher risk of autism spectrum disorders has been found in this group [37].

Limited information is available regarding the effects of LEV, TPM, and other ASDs on cognitive performance and behavior in later childhood [15]. In conclusion, regarding the intrauterine effects of ASDs on children of WWE, it is important to note the lack of reliable data for most currently prescribed ASDs. Further studies on this issue are required, and the absence of evidence of harm should not be interpreted as evidence of the safety of any given ASD. When preparing for pregnancy, patients should discuss the known risk and benefit information for individual ASDs that is available at the time.

#### **To summarize the key points on epilepsy and pregnancy:**


*Perspective Chapter: Epilepsy and Pregnancy DOI: http://dx.doi.org/10.5772/intechopen.111957*

7.Factors such as compliance, avoidance of smoking, alcohol and drug use, sufficient sleep (especially for IGE), identification and timely treatment of anxiety/depression, and repeated intake of ASDs in case of vomiting shortly after administration all contribute to maintaining a stable condition during pregnancy.

#### **3. Management of pregnancy in epilepsy**

#### **3.1 Therapy**

The protocols for treatment of pregnant WWE are based on expert opinions and consensuses and incorporate evidence-based practices. Nowadays, epilepsy treatment utilizes a variety of ASDs. The treatment approach emphasizes adherence to lifestyle recommendations, such as the avoidance of sleep deprivation, alcohol consumption, and reflex stimuli in reflex epilepsy. Additionally, it involves strict adherence to the prescribed medication regimen and use of the appropriate dosages prescribed by an epileptologist. Monotherapy with a single ASD at the minimum effective daily dose is the preferred approach. Combination therapy with two or, in rare cases, three ASDs that exhibit synergistic pharmacodynamics and pharmacokinetics may be considered if monotherapy proves ineffective [22].

#### *3.1.1 Drug therapy*

The latest recommendations from the working group on providing assistance to pregnant WWE suggest that LTG, LEV, OXC, and, to a lesser extent, CBZ are not significantly associated with the development of congenital malformations in fetus [15]. While, the use of VPA and phenobarbital in women of childbearing age is generally discouraged [38]. If discontinuation of these drugs is not possible during preparation for pregnancy, it is recommended to use two ASDs at a minimal dose of VPA, with LTG, LEV, OXC, or CBZ serving as potential additional options.

#### *3.1.2 Role of folic acid*

For several decades, the administration of folic acid to patients with epilepsy before conception and during pregnancy has been considered essential. Studies have shown that folate supplementation reduces the incidence of congenital heart defects [39], lowers the risk of autistic spectrum disorders [40], and contributes to increased IQ in children born to mothers with epilepsy who take ASDs [19]. Population studies have also indicated a positive effect of folic acid on the development of the nervous system, behavior, verbal abilities [41], although further research is needed to gain additional evidence.

The recommended daily dose of folic acid varies significantly, ranging from 0.4 mg/day [42] to 5 mg/day [15]. Higher doses of folate, exceeding 0.4 mg/day, are recommended in cases where a family history of malformations is identified. However, it is important to note that the administration of increased doses of folic acid has been associated with an increased risk of oncological diseases, cognitive disorders, and cleft palate [43]. Therefore, ongoing research in this area is necessary. In our work, we recommend regular intake of folic acid at a dose of 3 mg for 1–2 months before conception and during the first 12 weeks of pregnancy [22]. However,

obstetricians often recommend folate intake of at least 0.4 mg daily for women of childbearing age due to the high risk of unplanned pregnancies.

#### **3.2 Preparation for pregnancy**

Preparation for pregnancy begins during the puberty, when discussions about pregnancy and contraception are initiated with the patient and her relatives, including her mother and grandmother. Since epilepsy requires constant use of ASDs, the primary goal for a neurologist or an epileptologist is to achieve a seizure remission for at least 9 months prior to planned pregnancy using monotherapy with the minimum effective dosage of ASDs. Studies suggest that a period without seizures for 6 months is generally sufficient, but further research is needed to gather more data [2]. The need for continuous use of ASDs is justified by the fact that the risks associated with generalized seizures are greater for the patient and her child than the potential risks of continuous ASD usage [2, 15, 22, 23]. In preparation for pregnancy, in addition to selecting appropriate ASDs, a general physical examination is mandatory to exclude nonneurological diseases, particularly anemia, and assess the functional state of parenchymal organs involved in ASDs metabolism and elimination, namely the liver and kidneys.

The algorithm for preparing for pregnancy and managing pregnant WWE is presented in **Figure 1**. For ASDs such as LEV, LTG, OXC, ZNS, PHB, PHT, and benzodiazepines, it is important to consider the decrease in drug concentration due to increased renal blood flow starting from the end of the first trimester. Thus, physicians should be aware of the baseline concentration of ASD with variable pharmacokinetics before pregnancy and strive to maintain that baseline level throughout pregnancy. LTG exhibits the most significant changes in pharmacokinetics, with potential for threefold decrease in serum concentration, necessitating an increase in the daily dosage of the drug. The International League Against Epilepsy recommends monitoring these ASDs every 4 weeks, considering a clinically significant decrease in concentration by at least one-third of the original level. Therefore, if it is not possible to measure the ASD concentration during pregnancy, a 30–50% increase in the daily dosage is recommended at the end of the first trimester for patients on a minimal dose of ASDs with variable pharmacokinetics (LTG, LEV, OXC, ZNS, PHB, PHT), if these patients experience generalized tonic-clonic seizures or other seizure types associated with falls. The question of increasing the daily dosage should also be considered in cases of short-term, unstable remission in pregnant WWE with significant structural brain changes and in cases of polytherapy involving ASDs with variable pharmacokinetics [15].

#### **3.3 Assisted reproductive technologies**

During in vitro fertilization with high doses of estrogens, it is important to consider the possible recurrence of epileptic seizures, as estrogens have pro-epileptic effects unlike progesterone. Furthermore, the use of female steroid sex hormones can significantly affect the pharmacokinetics of LTG, a commonly used antiepileptic drug, leading to a reduction in its blood levels by 2 or more times. Therefore, in cases of long-lasting, persistent drug-induced clinical remission, it is recommended to continue regular use of antiepileptic drugs and maintain a consistent sleepwake cycle. Before performing ovarian stimulation procedures in patients with

*Perspective Chapter: Epilepsy and Pregnancy DOI: http://dx.doi.org/10.5772/intechopen.111957*

#### **Figure 1.**

*Algorithm for preparing for pregnancy, management of pregnancy and delivery in patients with epilepsy [22].*

insufficiently compensated primary disease state, it is desirable to assess the blood levels of antiepileptic drugs both initially and during sex hormone administration [22]. If the concentration of antiepileptic drugs is reduced by one-third, it is

recommended to increase the daily dose by 30–50%. If it is not possible to determine the concentration of LTG, its dosage should be increased by 50% before undergoing in vitro fertilization.

#### **3.4 Management of pregnancy in epilepsy**

There are formal contraindications to pregnancy, which include difficult-to-control epilepsy with frequent epileptic seizures accompanied by falls, generalized tonicclonic or focal to bilateral tonic-clonic seizures, status epilepticus, and marked personality changes posing a threat to the health and life of both the mother and the fetus [2, 22]. These contraindications are considered formal because if a woman decides to become pregnant, neurologists and obstetricians are obligated to use all possible means to preserve the pregnancy.

Given the certain risk of developing MCM, consultation with a geneticist is mandatory. Invasive methods of genetic testing may be performed based on specific indications.

In cases of compensated epilepsy with seizure remission, regular visits to the neurologist are required every 2 months, while visits to the obstetrician-gynecologist should follow standard guidelines. For patients experiencing focal seizures, more frequent visits to the neurologist every month are recommended, with visits to the obstetriciangynecologist occurring every 2–3 weeks. Patients and their relatives should be strongly advised to consult an epileptologist if seizures occur more frequently. Increased or exacerbated seizures may be caused by sleep deprivation, concurrent diseases, medication regimen violations, and others. Epilepsy itself is not an indication for pregnant women to receive inpatient treatment in a specialized neurological department.

The determination of ASD concentrations is performed every 2 months or less frequently during compensated epilepsy, and in cases of observed seizures, once a month or at every visit to the neurologist during pregnancy. During the first trimester of pregnancy, it is necessary to investigate the concentrations of ASDs with variable pharmacokinetics, including LTG, LEV, OXC, TPM, felbamate, and ZNS. It is known that clearance increases at the end of the first trimester due to increased renal blood flow, which can subsequently lead to decreased ASD concentrations. In the case of LTG, increase in clearance, glucuronidation and conjugation, can collectively reduce its concentration by up to three times [44, 45].

The concentrations of hormones of the fetoplacental complex (placental lactogen, progesterone, estriol, cortisol) and alpha-fetoprotein should be studied starting from the end of the first trimester of pregnancy and subsequently no less than once a month. Dynamic ultrasound examination of the fetus should be performed when the pregnant woman is registered, at 19–21 weeks (to exclude fetal developmental anomalies), and at 30–31 weeks. Starting from the 20th week of pregnancy, it is advisable to perform Doppler assessment of blood flow in the umbilical artery, aorta, and middle cerebral artery of the fetus during ultrasound examination, considering the high risk of developing placental insufficiency. When performing ultrasound associations of different congenital malformations, anomalies with certain ASDs should be taken into account.

From the 26th week of pregnancy, the use of cardiotocography is recommended to provide an objective assessment of uterine motility and fetal condition.

Diagnosis and treatment of fetal growth restriction and placental dysfunction should follow standard protocols. In patients with controlled epilepsy, i.e. in a state of medical (and non-medical) remission, there are no peculiarities in prenatal preparation [22].

#### **3.5 Status epilepticus**

The treatment of generalized tonic-clonic seizures and focal to bilateral tonicclonic seizures should follow the latest recommendations of 2020 [46]. Indications for Cesarean section include status epilepticus in the prepartum period. Status epilepticus of focal seizures without or with impaired consciousness and absence of status epilepticus does not serve as indications for pregnancy termination or C-section. All decisions regarding the treatment strategy and the prolongation of pregnancy during the status epilepticus should be made by a multidisciplinary team consisting of an obstetrician, neurologist, and anesthesiologist (perinatologist). Therefore, C-section is performed in all cases based on obstetric indications, except for status epilepticus in the prepartum period.

#### **3.6 Delivery, pain relief, and pregnancy outcomes**

Epilepsy is not a contraindication for vaginal delivery. Along with generally accepted obstetric indications, status epilepticus and uncontrolled increase in frequency of epileptic seizures in the prepartum period are grounds for performing a cesarean section [22].

Pharmacological intervention in labor and delivery and pain relief in epilepsy do not differ from the usual approach. Contraindications for epidural anesthesia are very rare, particularly in cases of impaired cerebrospinal fluid circulation due to acute cerebral and/or spinal pathology in the past.

Currently, there is insufficient data confirming or refuting the necessity of prescribing Vitamin K to a newborn during the early postpartum period when using ASDs with the aim to stimulate the cytochrome C450 enzymes [42]. Previous studies indicate a balance in the hemostasis system of newborns regardless of the ASDs used [47].

#### **3.7 Postpartum management**

Due to the risk of epileptic seizures during the postpartum period, the regular intake of prescribed ASD and sufficient rest are strongly recommended [2, 15].

The decrease in concentration of ASD required for seizure control after delivery can lead to the overdose, especially in cases of increased daily doses during pregnancy, potentially resulting in intoxication. There are reported cases of ASD overdose in the early postpartum period, with symptoms such as drowsiness, nystagmus, and ataxia in women, requiring a reduction in daily dosage and immediate monitoring of drug concentrations. The overdose of ASDs is attributed to a relative increase in concentration due to a mother weight decrease, blood loss during delivery, changes in ASD absorption, and other factors. Generally, returning to the daily dosage used before pregnancy is sufficient in the postpartum period, especially in cases when the daily dose of ASD was increased during pregnancy. According to the recommendations of Tomson et al. [1, 15], the normalization of lamotrigine pharmacokinetics occurs over the course of 3 weeks in the postpartum period [15]. However, there have been no observed signs of ASD overdose in the postpartum period in our practice [22].

If seizures persist or there is a risk of their occurrence or recurrence, it is recommended to have a relative constantly present with the mother. Seizures that can result in falls and harm the baby include generalized tonic-clonic, focal to bilateral

tonic-clonic, atonic, myoclonic, and myoclonic-tonic-clonic seizures. Any epileptic seizure with impairment of consciousness also poses a danger to the baby. In all these situations, the newborn care, including bathing, diapering, and carrying, should be done with constant assistance from relatives [22].

There is no justification for discontinuing breastfeeding of a newborn since, during pregnancy the fetus is usually exposed to higher concentrations of ASDs than a newborn receiving ASD through a breast milk [15]. Breastfeeding should be done in a lying position to prevent injury in case a seizure occurs.

**To summarize the key points on Management of Pregnancy in Epilepsy:**


#### **4. Conclusion**

Research on the topic of "Epilepsy and Pregnancy" is an ongoing process, but many aspects still need to be studied. The analysis of publications is challenging due to multiple limitations such as small sample sizes, insufficient study quality, ethical constraints on conducting placebo-controlled studies, and other factors. Therefore, the main recommendations for managing epilepsy in pregnancy are based on expert opinions rather than strictly high-level evidence-based research. Nevertheless,

*Perspective Chapter: Epilepsy and Pregnancy DOI: http://dx.doi.org/10.5772/intechopen.111957*

significant progress has been made in recent years. Notably, the publication of "Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy" [15] provides valuable insights into the main issues, directions for further research, and recommendations for preparing and managing pregnancy in patients with epilepsy. A condensed version of the article with key positions was also published [1]. In 2020, the same group of researchers conducted a global survey of International League Against Epilepsy (ILAE) national chapters to assess the current state of the problem worldwide. The survey revealed that many countries still rely on outdated or overly general guidelines, while information on the topic is continuously evolving. The working group plans to collaborate with the ILAE Wikipedia team to create a series of pages containing updated recommendations for pregnancy in women with epilepsy and their care, ensuring that the latest information becomes available [48].

#### **Conflict of interest**

The authors declare no conflict of interest.

### **Author details**

Pavel Vlasov Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia

\*Address all correspondence to: vpn\_neuro@mail.ru

© 2023 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### **References**

[1] Tomson T, Battino D, Bromley R, Kochen S, Meador K, Pennel P, et al. Management of epilepsy in pregnancy: A report from the international league against epilepsy task force on women and pregnancy. Epilepsia. 2019;**00**:1-3. DOI: 10.1111/epi.16395

[2] Karlov VA, Vlasov PN, Petrukhin VA, Zhidkova IA, Adamyan LV. Chapter 32.3 epilepsy and pregnancy. In: Karlov VA, editor. Epilepsy in Children and Adults, Women, and Men: A Guide for Physicians. 2nd ed. Moscow: BINOM Publishing House; 2019. pp. 672-691

[3] Watila MM, Beida O, Kwari S, et al. Seizure occurrence, pregnancy outcome among women with active convulsive epilepsy: One year prospective study. Seizure. 2015;**26**:7-11. DOI: 10.1016/j. seizure.2015.01.007

[4] De Lima LM, Toporcov TN, Dal Pai J, Claudio da Silva J. Socio-demographic profiles and obstetrics outcomes of pregnant women with epilepsy in a vulnerability state, Brazil. PLoS One. 2022;**17**(7):e0271328. DOI: 10.1371/ journal.pone.0271328

[5] Pennell PB, French JA, May RC, et al. Changes in seizure frequency and antiepileptic therapy during pregnancy. The New England Journal of Medicine. 2020;**383**(26):2547-2556. DOI: 10.1056/ NEJMoa2008663

[6] Harden CL, Hopp J, Ting TY, et al. Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the quality standards subcommittee and therapeutics and technology assessment Subcommittee of the American Academy of neurology and the American Epilepsy Society. Epilepsia. 2009;**50**:1229-1236. DOI: 10.1111/j.1528-1167.2009.02128.x

[7] Battino D, Tomson T, Bonizzoni E, et al. Seizure control and treatment changes in pregnancy: Observations from the EURAP epilepsy pregnancy registry. Epilepsia. 2013;**54**(9):1621-1627

[8] Voinescu PE, Ehlert AN, Bay CP, Allien S, Pennell PB. Variations in seizure frequency during pregnancy and postpartum by epilepsy type. Neurology. 2022;**98**:e802-e807. DOI: 10.1212/ WNL.0000000000013056

[9] Eadie MJ. Pregnancy and the control of epileptic seizures: A review. Neurology and Therapy. 2021;**10**(2):455-468. DOI: 10.1007/s40120-021-00252-5

[10] Reisinger TL, Newman M, Loring DW, Pennell PB, Meador KJ. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy & Behavior. 2013;**29**(1):13-18. DOI: 10.1016/j. yebeh.2013.06.026

[11] Cagnetti C, Lattanzi S, Foschi N, Provinciali L, Silvestrini M. Seizure course during pregnancy in catamenial epilepsy. Neurology. 2014;**83**:339-344. DOI: 10.1212/WNL.0000000000000619

[12] La Neve A, Boero G, Francavilla T, Plantamura M, De Agazio G, Specchio LM. Prospective, case-control study on the effect of pregnancy on seizure frequency in women with epilepsy. Neurological Sciences. 2015;**36**:79-83. DOI: 10.1007/ s10072-014-1908-0

[13] Shahla M, Hijran B, Sharif M. The course of epilepsy and seizure control *Perspective Chapter: Epilepsy and Pregnancy DOI: http://dx.doi.org/10.5772/intechopen.111957*

in pregnant women. Acta Neurologica Belgica. 2018;**118**:459-464. DOI: 10.1007/ s13760-018-0974-0

[14] Vajda FJ, O'Brien TJ, Lander CM, Graham J, Eadie MJ. Does pregnancy per se make epilepsy worse? Acta Neurologica Scandinavica. 2016;**133**:380- 383. DOI: 10.1111/ane.12479

[15] Tomson T, Battino D, Bromley R, Kochen S, Meador K, Pennell P, et al. Management of epilepsy in pregnancy: A report from the international league against epilepsy task force on women and pregnancy. Epileptic Disorders. 2019;**21**(6):497-517. DOI: 10.1684/ epd.2019.1105

[16] Edey S, Moran N, Nashef L. SUDEP and epilepsy-related mortality in pregnancy. Epilepsia. 2014;**55**(7):e72-e74. DOI: 10.1111/epi.12621

[17] Sahoo S, Klein P. Maternal complex partial seizure associated with fetal distress. Archives of Neurology. 2005;**62**(8):1304-1305. DOI: 10.1001/ archneur.62.8.1304

[18] Chen YH, Chiou HY, Lin HC, Lin HL. Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Archives of Neurology. 2009;**66**:979-984. DOI: 10.1001/ archneurol.2009.142

[19] Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): A prospective observational study. Lancet Neurology. 2013;**12**(3):244-252. DOI: 10.1016/ S1474-4422(12)70323-X

[20] Baker GA, Bromley RL, Briggs M, et al. IQ at 6 years after in utero exposure to antiepileptic drugs: A controlled cohort study. Neurology. 2015;**84**(4):382-390. DOI: 10.1212/WNL.0000000000001182

[21] Voinescu PE, Park S, Chen LQ, et al. Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy. Neurology. 2018;**91**(13):e1228-e1236. DOI: 10.1212/ WNL.0000000000006240

[22] Vlasov PN. Chapter 5. Epilepsy. In: Vlasov PN, Petrukhin VA, Avkhlediani KN, Lubnin AU, editors. Neurological Pathology and Pregnancy. Moscow: MEDPRESS-Inform; 2022. pp. 92-102. DOI: 10.24421/ v4294-7741-1383-x

[23] Dmitrenko DV, Schnaider NA, Goroshkin AN, Tomilina AI, Vlasov PN, Sapronova MR. Russian register of pregnancy and epilepsy. Neurology, Neuropsychiatry, Psychosomatics. 2017;**9**(1c):21-25. DOI: 10.14412/2074- 2711-2017-1S-21-25

[24] Pennell PB, Klein AM, Browning N, et al. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy & Behavior. 2012;**24**(4):449-456. DOI: 10.1016/j.yebeh.2012.05.010

[25] Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: A prospective cohort study of the EURAP registry. Lancet Neurology. 2018;**17**(6):530-538. DOI: 10.1016/ S1474-4422(18)30107-8

[26] Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;**78**(21):1692-1699. DOI: 10.1212/WNL.0b013e3182574f39

[27] Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: Updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Journal of Neurology,

Neurosurgery, and Psychiatry. 2014;**85**(9):1029-1034

[28] Vajda FJ, O'Brien TJ, Lander CM, Graham J, Eadie MJ. The teratogenicity of the newer antiepileptic drugs—An update. Acta Neurologica Scandinavica. 2014;**130**:234-238. DOI: 10.1111/ ane.12280

[29] Blotière PO, Raguideau F, Weill A, et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019;**93**(2):e167-e180. DOI: 10.1212/ WNL.0000000000007696

[30] Veiby G, Daltveit AK, Schjolberg S, et al. Exposure to antiepileptic drugs in utero and child development: A prospective population-based study. Epilepsia. 2013;**54**(8):1462-1472. DOI: 10.1111/epi.12226

[31] Meador KJ, Baker GA, Browning N, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011;**134**(2):396-404. DOI: 10.1093/ brain/awq352

[32] Bromley RL, Calderbank R, Cheyne CP, et al. Cognition in schoolage children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 2016;**87**(18):1943-1953. DOI: 10.1212/WNL.0000000000003157

[33] Huber-Mollema Y, Oort FJ, Lindhout D, Rodenburg R. Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy. Epilepsia. 2019;**60**(6):1069-1082

[34] Bromley RL, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: Neurodevelopmental outcomes in

the child. Cochrane Database of Systematic Reviews. 2014;**10**:CD010236. DOI: 10.1002/14651858.CD010236.pub2

[35] Meador KJ, Baker GA, Browning N, et al. Breastfeeding in children of women taking antiepileptic drugs: Cognitive outcomes at age 6 years. JAMA Pediatrics. 2014;**168**(8):729-736. DOI: 10.1001/ jamapediatrics.2014.118

[36] Elkjaer LS, Bech BH, Sun Y, Laursen TM, Christensen J. Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurology. 2018;**75**(6):663-671. DOI: 10.1001/ jamaneurol.2017.5035

[37] Bromley RL, Mawer GE, Briggs M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery, and Psychiatry. 2013;**84**(6):637-643. DOI: 10.1136/ jnnp-2012-304270

[38] Avakyan GN, Blinov DV, Avakyan GG, et al. Limitations of the use of valproic acid in girls and women: Expansion of contraindications in the instructions for medical use based on real clinical practice data. Epilepsy and Paroxysmal Conditions. 2019;**11**(2):110-123

[39] Czeizel AE, Dudas I, Vereczkey A, Banhidy F. Folate deficiency and folic acid supplementation: The prevention of neural-tube defects and congenital heart defects. Nutrients. 2013;**5**(11):4760-4775. DOI: 10.3390/nu5114760

[40] Bjork M, Riedel B, Spigset O, et al. Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs in utero. JAMA Neurology.

*Perspective Chapter: Epilepsy and Pregnancy DOI: http://dx.doi.org/10.5772/intechopen.111957*

2018;**75**(2):160-168. DOI: 10.1001/ jamaneurol.2017.3897

[41] Husebye ES, Gilhus NE, Riedel B, Spigset O, Daltveit AK, Bjork MH. Verbal abilities in children of mothers with epilepsy: Association to maternal folate status. Neurology. 2018;**91**(9):e811-e821. DOI: 10.1212/WNL.0000000000006073

[42] Harden CL, Pennell PB, Koppel BS, et al. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breastfeeding: Report of the quality standards subcommittee and therapeutics and technology assessment Subcommittee of the American Academy of neurology and the American Epilepsy Society. Epilepsia. 2009;**50**(5):1247-1255. DOI: 10.1111/j.1528-1167.2009.02130.x

[43] Murray LK, Smith MJ, Jadavji NM. Maternal oversupplementation with folic acid and its impact on neurodevelopment of offspring. Nutrition Reviews. 2018;**76**(9):708-721. DOI: 10.1093/nutrit/ nuy025

[44] Reimers A, Helde G, Bråthen G, Brodtkorb E. Lamotrigine and its N2-glucuronide during pregnancy: The significance of renal clearance and estradiol. Epilepsy Research. 2011;**94**(3):198-205. DOI: 10.1016/j. eplepsyres.2011.02.002

[45] Karanam A, Pennell PB, French JA, et al. Lamotrigine clearance increases by 5 weeks gestational age: Relationship to estradiol concentrations and gestational age. Annals of Neurology. 2018;**84**(4):556-563. DOI: 10.1002/ ana.25321

[46] Minicucci F, Ferlisi M, Brigo F, Mecarelli O, Meletti S, Aguglia U, et al. Management of status epilepticus in adults. Position paper of the Italian

league against epilepsy. Epilepsy & Behavior. 2020:102. DOI: 10.1016/j. yebeh.2019.106675

[47] Vlasov PN, Drojina GR, Petrukchin VA, Grishin VL, Melnikov AP. Haemostatic parameters of newborns from mothers with epilepsy. Epileptologia. 2012;**20**(1):5-9

[48] Tomson T, Battino D, Bromley R, et al. Global survey of guidelines for the Management of Epilepsy in pregnancy: A report from the international league against epilepsy task force on women and pregnancy. Epilepsia Open. 2020;**5**:366- 370. DOI: 10.1002/epi4.12420

Section 2
